Skip to main content

Advertisement

SpringerLink
Log in

A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated. Between 1990 and 1996, 20 patients (11 males and nine females, median age of 49 years [range 30–75 years]) were treated with carboplatin, 250 mg/m2/day × 5 days as an infusion and mitoxantrone, 10 mg/m2/day × 3 days, IV bolus. Median time from diagnosis of CML to BC was 4.25 years (range 0–11 years). CMLBC was myeloid in 13 patients, lymphoid in six, and megakaryocytic in one. All patients were Philadelphia (Ph) chromosome positive; four had a single Ph chromosome, five had double Ph chromosome, three had abnormalities of chromosome 17, and eight had complex cytogenetic abnormalities. Prior treatment for chronic phase included hydroxyurea (12 patients), interferon-α (11 patients), cytarabine or all-trans retinoic acid, three patients each and other agents (four patients). Eight patients (five myeloid and three lymphoid) had an objective response (median duration, 3 months). Five had complete responses (CR) of 2, 3, 3, 6, and 6+ months duration, and three had partial responses (PR) for 1, 2, and 4 months. Seven patients died too early to evaluate (TETE): three died pancytopenic in <30 days from initiation of chemotherapy, two patients had pancytopenia for >30 days but had only blasts in their day 30 bone marrow, and two patients were pancytopenic >30 days but demonstrated trilineage marrow regeneration. Three of eight responders survived ≥1 year. Toxicity was primarily hematologic. The objective response rate was 61% (8/13) among those who did not die TETE and 40% among all treated patients. Carboplatin plus mitoxantrone are highly active in CMLBC, with marrow aplasia as the dose-limiting toxicity, and these agents deserve further study in CMLBC, perhaps in combination with tyrosine kinase inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arlin ZA, Silver RT, Bennett JM. Blastic phase of chronic myeloid leukemia (blCML): a proposal for standardization of diagnostic and response criteria. Leukemia. 1990;4:755–7.

    PubMed  CAS  Google Scholar 

  2. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med. 1999;131:207–19.

    PubMed  CAS  Google Scholar 

  3. Greisshamer M, Heinze B, Hellmann A, et al. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol. 1996;73:225–30.

    Article  Google Scholar 

  4. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441–6.

    Article  PubMed  CAS  Google Scholar 

  5. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia. A concise update. Blood. 1993;82:691–703.

    PubMed  CAS  Google Scholar 

  6. Wiernik PH. The current status of therapy for and prevention of blast crisis of chronic myelocytic leukemia. J Clin Oncol. 1984;2(4):329–35.

    PubMed  CAS  Google Scholar 

  7. Axdorph U, Stenke L, Grimfors G, et al. Intensive chemotherapy in patients with chronic myelogenous leukemia (CML) in accelerated or blastic phase—a report from the Swedish CML group. Br J Haematol. 2002;118:1048–54.

    Article  PubMed  CAS  Google Scholar 

  8. Bolaman Z, Koseoglu M, Ayyildiz O, et al. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone. Hematologica. 2002;32:49–57.

    CAS  Google Scholar 

  9. Dutcher JP, Eudey L, Wiernik PH, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia. 1992;6:770–5.

    PubMed  CAS  Google Scholar 

  10. Kantarjian HM, Walters RS, Keating MJ, et al. Treatment of blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988;62:672–6.

    Article  PubMed  CAS  Google Scholar 

  11. Robak T, Gora-Tybor J. Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia. Neoplasma. 2001;48:203–7.

    PubMed  CAS  Google Scholar 

  12. Perez-Simon JA, Caballero MD, Hernandez-Rivas JM, et al. Complete cytogenetic but not molecular remission in a patient with myeloid blast crisis of chronic myeloid leukemia treated with carboplatin and ara-c. Hematologica. 1997;82:604–5.

    CAS  Google Scholar 

  13. Dutcher JP, Strauman JJ, Paciucci PA, et al. Mitoxantrone and cytosine arabinoside for the treatment of chronic myelogenous leukemia—blast crisis (CML-BC). Proc Am Soc Clin Oncol. 1986;5:166.

    Google Scholar 

  14. Schiffer CA, DeBellis R, Kasdorf H, et al. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Cancer Treat Rep. 1982;66:267–71.

    PubMed  CAS  Google Scholar 

  15. Drucker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42.

    Article  Google Scholar 

  16. Dutcher JP, Lee S, Paietta E, et al. Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group study, E 1992. Leukemia. 1998;12:1037–40.

    Article  PubMed  CAS  Google Scholar 

  17. Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  18. Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics. 1985;41:741–4.

    Article  PubMed  CAS  Google Scholar 

  19. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445–54.

    Article  PubMed  CAS  Google Scholar 

  20. Cortes J, Talpaz M, O’Brien S, et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998;16:3279–85.

    PubMed  CAS  Google Scholar 

  21. Kurzrock R, Estrove Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998;16:1526–31.

    PubMed  CAS  Google Scholar 

  22. Kantarjian HM, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to Imatinib Mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–52.

    Article  PubMed  CAS  Google Scholar 

  23. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Hematologica. 2003;88:1213–20.

    CAS  Google Scholar 

  24. Palandri F, Castagnetti F, Testone N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Hematologica. 2008;93:1792–6.

    Article  CAS  Google Scholar 

  25. Vogler R, Harrington DP, Winton EF, et al. Phase II clinical trial of carboplatin in relapsed and refractory leukemia. Leukemia. 1992;6:1072–5.

    PubMed  CAS  Google Scholar 

  26. Silver RT, Cortes J, Wallzman R, et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Hematologica. 2009;94:743–4.

    Article  Google Scholar 

  27. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007;48:283–9.

    Article  PubMed  CAS  Google Scholar 

  28. Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007;109:1543–9.

    Article  PubMed  CAS  Google Scholar 

  29. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007;109:899–906.

    Article  PubMed  CAS  Google Scholar 

  30. Rea D, Legros L, Raffoux E, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006;20:400–3.

    Article  PubMed  CAS  Google Scholar 

  31. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207–13.

    Article  PubMed  CAS  Google Scholar 

  32. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008;22:2176–83.

    Article  PubMed  CAS  Google Scholar 

  33. Shah NP. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw. 2008;6 suppl 2:S31–6.

    PubMed  Google Scholar 

  34. Wang Y, Wu D, Sun A, et al. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. Int J Hematol. 2008;87:167–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Bruce Gaynor

    Present address: FI Proctor Foundation and Department of Ophthalmology, University of California, San Francisco, USA

Authors and Affiliations

  1. New York Medical College, 600 East 233rd Street, Bronx, NY, 10466, USA

    Janice P. Dutcher, Evelyn L. Morris, Bruce Gaynor, Elisabeth Paietta & Peter H. Wiernik

Authors
  1. Janice P. Dutcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evelyn L. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruce Gaynor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth Paietta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter H. Wiernik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janice P. Dutcher.

Additional information

Supported in part by the Leukemia Fund of the Cancer Research Foundation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dutcher, J.P., Morris, E.L., Gaynor, B. et al. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. Med Oncol 27, 728–735 (2010). https://doi.org/10.1007/s12032-009-9276-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9276-y

Keywords

Search

Navigation